Latest news
Liver Cancer Is Moving Beyond TACE Alone
EMERALD-3 showed that adding the STRIDE immunotherapy regimen to TACE improved progression-free survival in embolization-eligible unresectable hepatocellular carcinoma. The result could shift practice, but the toxicity and implementation questions are not small.
The Trial Has Started. Now the System Has to Find the Children.
572 Sick. Still No Food Name.
IPM Brief – Issue 9 | The System Knows. The Patient Still Waits.
Bangladesh’s Dengue Alarm Is Already Ringing
Sleep is now cardiovascular prevention. Health systems still treat it like lifestyle advice
The GLP-1 boom still needs exercise policy
Europe Opens Another Lung Cancer Door to China-Origin Immunotherapy
In Australia, Cancer Medicine Delays Cost More Than Time
ADHD Does Not Stop Being ADHD When Anxiety Walks Into the Room
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.